THERAPY DOSSIER · th-431a81bbe960

Interleukin-19 (exogenous)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30460984 ↗2019Reported benefit

Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction.

MouseIschaemia-reperfusionCardiacC57BL/6MaleIntraperitoneal10 ng per g

Model: Myocardial infarction produced by ligation of the left anterior descending coronary artery, with a parallel in vitro oxygen-glucose deprivation model in cultured neonatal mouse ventricular myocytes

Exogenous interleukin-19 reduced infarct size, apoptosis, oxidative stress and pro-inflammatory cytokines, promoted M2 polarisation and angiogenesis, and preserved cardiac function and improved survival after myocardial infarction.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…